Source: Zacks

Fate Therapeutics: Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus.

Read full article »
Fate Therapeutics's Competitors | Fate Therapeutics's News | Fate Therapeutics's Financials
Stay up-to-date with the latest news on Fate Therapeutics
Annual Revenue
$5.0-25M
Employees
100-250
Bahram Valamehr's photo - President & CEO of Fate Therapeutics

President & CEO

Bahram Valamehr

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Fate Therapeutics